Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

seekingalpha.com - SA Transcripts - InnoCare Pharma Limited (INCPF) Q4 2025 Earnings Call Transcript
InnoCare Pharma Limited (INCPF) Q4 2025 Earnings Call Transcript
Seeking Alpha

InnoCare Pharma Limited (INCPF) Q4 2025 Earnings Call March 25, 2026 8:30 AM EDT Jisong Cui - Co-Founder, Chairwoman & CEO Xin Fu - Chief Financial Officer Renbin Zhao - Senior VP of Clinical Development & Medical Research and Executive Director…

seekingalpha.com - SA Transcripts - Ascentage Pharma Group International (AAPG) Q4 2025 Earnings Call Transcript
Ascentage Pharma Group International (AAPG) Q4 2025 Earnings Call Transcript
Seeking Alpha

Ascentage Pharma Group International (AAPG) Q4 2025 Earnings Call March 26, 2026 8:00 AM EDT Dajun Yang - Co-Founder, Chairman & CEO Veet Misra - Chief Financial Officer Zhichao Si - Head of Commercial Lut Ming Cheng - JPMorgan Chase & Co, Research…

redstate.com - Jennifer Oliver O'Connell - CPAC 2026: Team CMS, Dr. Oz Talk Beating Big Pharma and Fraud, Following 'North Star' of Truth
CPAC 2026: Team CMS, Dr. Oz Talk Beating Big Pharma and Fraud, Following 'North Star' of Truth
redstate.com

At Thursday's CPAC (Conservative Political Action Conference), held in 2026 by the American Conservative Union (ACU) in Texas, the top officials at the Centers for Medicare & Medicaid Services Administrator (CMS) sat down with ACU Chairman Matt…

marketbeat.com - Royalty Pharma PLC (NASDAQ:RPRX) Given Average Rating of 'Buy' by Analysts
Royalty Pharma PLC (NASDAQ:RPRX) Given Average Rating of 'Buy' by Analysts
MarketBeat

Shares of Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) have been given a consensus recommendation of 'Buy' by the six research firms that are covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a…

marketbeat.com - Spyglass Pharma (NASDAQ:SGP) Releases Earnings Results, Beats Expectations By $0.89 EPS
Spyglass Pharma (NASDAQ:SGP) Releases Earnings Results, Beats Expectations By $0.89 EPS
MarketBeat

Spyglass Pharma (NASDAQ:SGP - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($5.72) earnings per share for the quarter, topping analysts' consensus estimates of ($6.61) by $0.89, Zacks reports. Shares of…

marketbeat.com - OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update
MarketBeat

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) saw a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 275,291 shares, a decline of 36.8% from the February 26th total of…

marketbeat.com - Ascentage Pharma Group International (NASDAQ:AAPG) Given 'Buy' Rating at BTIG Research
Ascentage Pharma Group International (NASDAQ:AAPG) Given 'Buy' Rating at BTIG Research
MarketBeat

Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report)'s stock had its 'buy' rating reissued by analysts at BTIG Research in a note issued to investors on Thursday, Benzinga reports. They currently have a $48.00 price objective on the…

washingtonexaminer.com - James Edwards - Big Tech's patent battering ram isn't lowering drug prices
Big Tech's patent battering ram isn't lowering drug prices
Washington Examiner

Marketed as a cheap, quick alternative to federal courts for patent invalidity challenges, PTAB soon morphed into Big Tech's battering ram. It has wielded PTAB relentlessly against smaller innovators' patents. Big Tech files challenge after…

cnbc.com - Elsa Ohlen - Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
CNBC

Novartis' acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company's existing allergy portfolio. It comes just a week after Novartis announced it is acquiring Synnovation subsidiary Pikavation Therapeutics…

seekingalpha.com - Columbia Threadneedle Investments - Columbia Select Large Cap Growth Fund Q4 2025 Commentary (ELGAX)
Columbia Select Large Cap Growth Fund Q4 2025 Commentary (ELGAX)
Seeking Alpha

Columbia Select Large Cap Growth Fund Institutional Class shares returned 1.16% for the three months ending December 31, 2025. The U.S. Federal Reserve continued to ease policy, cutting rates by a quarter point at its meetings in October and…

thehindu.com - Shilpa Nair Anand - Theatre director PR Arun explores gender, violence and patriarchy in his latest production Hand of God
Theatre director PR Arun explores gender, violence and patriarchy in his latest production Hand of God
The Hindu

Hand of God explores consent and violence in intimate relationships to show how love, marriage, and power become tools of control. The installation pivots marital rape, and because of the interactive nature of its conception, the play demands its…

cyclingnews.com - Cycling News - Amstel Gold Race past winners
Amstel Gold Race past winners
Cyclingnews

Amstel Gold Race past winners Year Mattias Skjelmose (Den) Lidl-Trek Tom Pidcock (Gbr) Ineos Grenadiers Tadej Pogačar (Slo) UAE Team Emirates Michal Kwiatkowski (Pol) Ineos Grenadiers Wout van Aert (Bel) Jumbo-Visma Mathieu van der Poel (Ned)…

cnbc.com - Davis Giangiulio - Stocks making the biggest moves midday: Brown-Forman, Entergy, Meta Platforms, Carnival, Argan & more
Stocks making the biggest moves midday: Brown-Forman, Entergy, Meta Platforms, Carnival, Argan & more
CNBC

Here are some of the stocks making headlines in midday trading. Entergy — The utility stock popped more than 8% after the firm announced a deal with Meta to support the hyperscale data center in Northeast Louisiana. The agreement is expected…

barchart.com - Jim Van Meerten - Investors Have Been Waiting to Buy the Dip in This Hot Biopharma Stock
Investors Have Been Waiting to Buy the Dip in This Hot Biopharma Stock
Barchart.com

Jazz Pharmaceuticals (JAZZ) is a specialty biopharma company focused on neuroscience and oncology. JAZZ exhibits strong technical momentum. Shares are up nearly 50% over the past year. The stock maintains a 100% “Buy” technical…

thehindubusinessline.com - Sensex, Nifty slide close to 2% amid global selloff, IT stocks buck trend, ONGC leads gainer, TMPV, IndiGo, Bajaj twin shares top losers
Sensex, Nifty slide close to 2% amid global selloff, IT stocks buck trend, ONGC leads gainer, TMPV, IndiGo, Bajaj twin shares top losers
BusinessLine

Equity benchmarks traded sharply lower on Friday, tracking a global market selloff triggered by rising geopolitical tensions and weaker economic outlooks, while the rupee tumbled to hit a fresh all-time low of 94.70 against the US dollar, pressured…

Receive a Daily briefing on Pharma Industry News

Get Started